Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine disorders, rose 17% as of 11:45 a.m. EDT Thursday.
Here's a review of the key takeaways from the company's third quarter:
Commenting on the quarter, CEO Kevin Gorman stated:
Source: Fool.com
Neurocrine Bioscience Stock
€109.15
-0.820%
The stock is an absolute favorite of our community with 42 Buy predictions and no Sell predictions.
As a result the target price of 155 € shows a positive potential of 42.01% compared to the current price of 109.15 € for Neurocrine Bioscience.
